These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 38715994)

  • 1. Clinical Efficacy and Safety of Low-Dose Pemafibrate in Patients With Severe Renal Impairment: A Retrospective Study.
    Shima H; Tashiro M; Inoue T; Okada K; Okamoto T; Wariishi S; Doi T; Minakuchi J
    Cureus; 2024 Apr; 16(4):e57777. PubMed ID: 38715994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-Term Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor-α Modulator (SPPARMα), in Dyslipidemic Patients with Renal Impairment.
    Yokote K; Yamashita S; Arai H; Araki E; Suganami H; Ishibashi S; Of The K-Study Group OB
    Int J Mol Sci; 2019 Feb; 20(3):. PubMed ID: 30736366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases.
    Yamashita S; Masuda D; Matsuzawa Y
    Curr Atheroscler Rep; 2020 Jan; 22(1):5. PubMed ID: 31974794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world Profile of a Selective Peroxisome Proliferator-activated Receptor α Modulator (SPPARMα) in Japanese Patients with Renal Impairment and Dyslipidemia.
    Komatsu T; Miura T; Joko K; Sunohara D; Mochidome T; Kasai T; Ikeda U
    Intern Med; 2021 Sep; 60(17):2741-2748. PubMed ID: 33776008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of pemafibrate, a novel selective peroxisome proliferator-activated receptor-alpha modulator (SPPARMα), on urinary protein excretion in IgA nephropathy with hypertriglyceridemia.
    Tanaka A; Nakamura T; Sato E; Chihara A; Node K
    CEN Case Rep; 2020 May; 9(2):141-146. PubMed ID: 31950425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential effects on renal function and glucose metabolism of renal dependent bezafibrate and non-renal dependent pemafibrate in patients with hypertriglyceridemia.
    Nishida M; Horio T; Fukuda Y; Hayakawa Y; Tateishi Y; Akai M; Emoto M; Hasegawa T; Imanishi M
    Int J Clin Pharmacol Ther; 2023 Oct; 61(10):437-444. PubMed ID: 37548458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Applications of a Novel Selective PPARα Modulator, Pemafibrate, in Dyslipidemia and Metabolic Diseases.
    Yamashita S; Masuda D; Matsuzawa Y
    J Atheroscler Thromb; 2019 May; 26(5):389-402. PubMed ID: 30930344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Significant Increase of Estimated Glomerular Filtration Rate After Switching From Fenofibrate to Pemafibrate in Type 2 Diabetic Patients.
    Yanai H; Katsuyama H; Hakoshima M
    Cardiol Res; 2021 Dec; 12(6):358-362. PubMed ID: 34970366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Half Dose Once-Daily Pemafibrate Effectively Improved Hypertriglyceridemia in Real Practice.
    Iitake C; Iitake K
    J Clin Med Res; 2019 Oct; 11(10):690-695. PubMed ID: 31636783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator, Pemafibrate, on Metabolic Parameters: A Retrospective Longitudinal Study.
    Yanai H; Katsuyama H; Hakoshima M
    Biomedicines; 2022 Feb; 10(2):. PubMed ID: 35203610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial.
    Ishibashi S; Arai H; Yokote K; Araki E; Suganami H; Yamashita S;
    J Clin Lipidol; 2018; 12(1):173-184. PubMed ID: 29203092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and methods of an open-label, randomized controlled trial to evaluate the effect of pemafibrate on proteinuria in CKD patients (PROFIT-CKD).
    Seki M; Nakano T; Tanaka S; Matsukuma Y; Funakoshi K; Ohkuma T; Kitazono T
    Clin Exp Nephrol; 2023 Apr; 27(4):358-364. PubMed ID: 36738362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of pemafibrate in patients with chronic kidney disease: A retrospective study.
    Iwasaki M; Suzuki H; Umezawa Y; Koshida T; Saito M; Fukuda H; Takahara H; Matsuzaki K; Suzuki Y
    Medicine (Baltimore); 2023 Feb; 102(7):e32818. PubMed ID: 36800602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Pemafibrate on Serum Creatinine in Patients with Chronic Kidney Disease.
    Imai E; Imai A
    JMA J; 2022 Jul; 5(3):328-333. PubMed ID: 35992291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of pemafibrate in patients with hypertriglyceridemia in clinical settings: A retrospective study.
    Katakura Y; Shimoda M; Ohnishi M; Kusano T; Dan K; Isobe H; Wamata R; Iwamoto Y; Fushimi Y; Sanada J; Obata A; Kimura T; Tatsumi F; Nakanishi S; Mune T; Kaku K; Kaneto H
    Nutr Metab Cardiovasc Dis; 2023 Jul; 33(7):1444-1452. PubMed ID: 37246074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pemafibrate inhibited renal dysfunction and fibrosis in a mouse model of adenine-induced chronic kidney disease.
    Horinouchi Y; Murashima Y; Yamada Y; Yoshioka S; Fukushima K; Kure T; Sasaki N; Imanishi M; Fujino H; Tsuchiya K; Shinomiya K; Ikeda Y
    Life Sci; 2023 May; 321():121590. PubMed ID: 36940907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα): Pooled Analysis of Phase 2 and 3 Studies in Dyslipidemic Patients with or without Statin Combination.
    Yamashita S; Arai H; Yokote K; Araki E; Matsushita M; Nojima T; Suganami H; Ishibashi S
    Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31698825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of a novel selective peroxisome proliferator-activated receptor-α modulator, pemafibrate, on hepatic and peripheral glucose uptake in patients with hypertriglyceridemia and insulin resistance.
    Matsuba I; Matsuba R; Ishibashi S; Yamashita S; Arai H; Yokote K; Suganami H; Araki E
    J Diabetes Investig; 2018 Nov; 9(6):1323-1332. PubMed ID: 29603684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk.
    Das Pradhan A; Glynn RJ; Fruchart JC; MacFadyen JG; Zaharris ES; Everett BM; Campbell SE; Oshima R; Amarenco P; Blom DJ; Brinton EA; Eckel RH; Elam MB; Felicio JS; Ginsberg HN; Goudev A; Ishibashi S; Joseph J; Kodama T; Koenig W; Leiter LA; Lorenzatti AJ; Mankovsky B; Marx N; Nordestgaard BG; Páll D; Ray KK; Santos RD; Soran H; Susekov A; Tendera M; Yokote K; Paynter NP; Buring JE; Libby P; Ridker PM;
    N Engl J Med; 2022 Nov; 387(21):1923-1934. PubMed ID: 36342113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of pemafibrate on lipid metabolism in patients with type 2 diabetes and hypertriglyceridemia: A multi-center prospective observational study, the PARM-T2D study.
    Kito K; Nomoto H; Sakuma I; Nakamura A; Cho KY; Kameda H; Miya A; Omori K; Yanagiya S; Handa T; Taneda S; Takeuchi J; Nagai S; Yamashita K; Kurihara Y; Atsumi T; Miyoshi H;
    Diabetes Res Clin Pract; 2022 Oct; 192():110091. PubMed ID: 36174777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.